HUGO ID Detailed Result 10618

HUGO ID 10618
Symbol CCL2
Name chemokine (C-C motif) ligand 2
#Occurrence 101
#Paper 8

 

PMID Match String Actual String Score Flanking text Edited by Edit
14597108MCP-1MCP-12.8Monocyte-chemoattractant protein (MCP-1) MCP-1 might play an important role in microglial recruitment 
14597108MCP-1MCP-12.8We studied MCP-1 levels in sera and cerebrospinal fluid of 29 ALS patients 
14597108MCP-1MCP-12.8The MCP-1 level was determined using enzyme-linked immunosorbent assays (ELISA) ELISA 
14597108MCP-1MCP-12.8A significant increase in cerebrospinal fluid MCP-1 level but not serum level was seen in the patients 
14597108MCP-1MCP-12.8These results suggest that cerebrospinal fluid MCP-1 activity may be a sensitive marker for neuroinflammation in ALS 
14597108MCP-1MCP-12.8Especially monocyte chemoattractant protein-1 (MCP-1) MCP-1 Maghazachi et al. 1994 may be a key trigger for 
14597108MCP-1MCP-12.8MCP-1 was found immunohistochemically in mature senile plaques and reactive microglia 
14597108MCP-1MCP-12.8Changes in MCP-1 in living patients with ALS have not been studied however 
14597108MCP-1MCP-12.8Therefore the present study compares the MCP-1 level in CSF and serum of patients with ALS with 
14597108MCP-1MCP-12.8MCP-1 levels in serum and CSF samples were quantified by ELISA 
14597108MCP-1MCP-12.8The Mann_amp_#x2013 Whitney U -test was used to compare MCP-1 levels in CSF and serum in ALS patients with controls 
14597108MCP-1MCP-12.8relationship between age at time of lumbar puncture and intrathecal MCP-1 levels 3 
14597108MCP-1MCP-12.8The CSF concentration of MCP-1 was significantly ( p _amp_#x3c 0.001 higher in ALS patients 
14597108MCP-1MCP-12.8an overlap of values was seen among the ALS group MCP-1 values of only 8 patients of 29 were lower than 
14597108MCP-1MCP-12.8Furthermore MCP-1 levels in ALS patients (570.5_amp_#xb1;199.9 570.5_amp_#xb1 199.9 pg/ml) pg ml 
14597108MCP-1MCP-12.8onset of symptoms nor of duration of the disease on MCP-1 levels 
14597108MCP-1MCP-12.8relationship between age at time of lumbar puncture and intrathecal MCP-1 level in ALS patients ( r =0.045 Fig 1a or 
14597108MCP-1MCP-12.8This is the first study demonstrating that MCP-1 inflammatory signalling might mediate recruitment of myelomonocytic cells to areas 
14597108MCP-1MCP-12.8provide in vivo evidence for elevated cerebrospinal fluid levels of MCP-1 in ALS patients providing further evidence for the hypothesis that 
14597108MCP-1MCP-12.8The higher levels of MCP-1 in the CSF than in paired serum samples in patients 
14597108MCP-1MCP-12.8activation of astrocytes and microglial cells induces a release of MCP-1 a chemokine produced by both glial cell types Hayashi et 
14597108MCP-1MCP-12.8Since MCP-1 is a potent activator of macrophage function and specifically attracts 
14597108MCP-1MCP-12.8Therefore one might speculate that MCP-1 might further increase during the course of ALS 
14597108MCP-1MCP-12.8Repetitive measurement of MCP-1 may be a useful laboratory marker to follow-up patients participating 
14597108MCP-1MCP-12.8between clinical impairment/progression impairment progression of the disease and CSF MCP-1 levels a larger sample size may be needed to address 
14597108MCP-1MCP-12.8In experimental autoimmune encephalomyelitis absence of MCP-1 in mice leads to decreased local macrophage recruitment and antigen-specific 
14597108MCP-1MCP-12.8note is that bindarit an indazolic derivative able to inhibit MCP-1 is able to ameliorate adjuvant arthritis in rats Guglielmotti et 
14597108MCP-1MCP-12.8The present data suggest that MCP-1 levels in CSF may be an appropriate surrogate marker in 
14597108MCP-1MCP-12.8worthwhile to examine the prognostic value of CSF/plasma CSF plasma MCP-1 ratios in ALS patients who are followed longitudinally which should 
14597108MCP-1MCP-12.8between age at the time of lumbar puncture and intrathecal MCP-1 levels in ALS patients (a) a and control patients (b) 
15210305MCP-1MCP-11.6beta deposition activates astrocytes and oligodendrocytes to produce chemokines (MCP-1 MCP-1 and RANTES which act as potent in vitro microglial and 
15962273MCP-1MCP-12.8Monocyte chemoattractant protein-1 (MCP-1) MCP-1 is critical for recruitment of inflammatory cells of monocytic lineage 
15962273MCP-1MCP-12.8MCP-1 concentrations were measured by an enzyme-linked immunosorbent assay in the 
15962273MCP-1MCP-12.8In ALS circulating MCP-1 levels were significantly increased in the serum and particularly in 
15962273MCP-1MCP-12.8Immunoreactivity for MCP-1 in ALS spinal cord was detected mostly in astrocytes but 
15962273MCP-1MCP-12.8Our findings suggest a role for MCP-1 as an important molecular mediator of the injury response in 
16624536MCP-1MCP-12.3Increased levels of monocyte chemoattractant protein-1 (MCP-1) MCP-1 are seen in the cerebrospinal fluid (CSF) CSF from ALS 
16624536MCP-1MCP-12.3Monocyte chemoattractant protein-1 (MCP-1) MCP-1 is critical for migration of monoctyes to areas of injury 
16624536MCP-1MCP-12.3discussed in relation to adaptive and acquired immunity in ALS MCP-1 concentrations are significantly increased in both serum and cerebrospinal fluid 
16624536MCP-1MCP-12.3MCP-1 immunoreactivity is highest in astrocytes in ALS spinal cord suggesting 
16753239MCP-1MCP-11.3as the cytokines IL-1_amp_#x3b2 IL-6 and TNF-_amp_#x3b1 and the chemokine MCP-1 by both primary mouse microglia and astrocytes ( Storer et 
16753239MCP-1MCP-11.3pro-inflammatory cytokines TNF-_amp_#x3b1 IL-1_amp_#x3b2 IL-6 IL-12 p40 and the chemokine MCP-1 by primary mouse microglia 
16753239MCP-1MCP-11.3in inhibiting LPS induction of NO TNF-_amp_#x3b1 IL-1_amp_#x3b2 IL-6 and MCP-1 expression in primary astrocytes (unpublished unpublished data 
17569578MCP1MCP11.3been shown to reduce the expression of the monocytic chemoattractant MCP1 95 IP-10 (CXCL3), CXCL3 MIG and I-TAC 117 
18040778CCL2CCL20.3amounts of several cytokines/chemokines, cytokines chemokines including TNF-A IL-6 IL-1B CCL2 CCL5 and CXCL10 
18040778CCL2CCL20.4the presence of specific antibody human microglia produce CCL3 CCL4 CCL2 CXCL8 and low levels of CCL5 via Fc-receptor activation (Goldman 
18464925MCP-1MCP-12.6of proinflammatory cytokines and the chemokine monocyte chemoattractant protein-1 (MCP-1) MCP-1 73 78 
14597108mcp 1mcp 11.0monocyte chemoattractant protein mcp 1 might play an important role in microglial recruitment.  
14597108mcp 1mcp 11.0we studied mcp 1 levels in sera and cerebrospinal fluid of 29 als patients and compared the results with 11 control patients with tension headache.  
14597108mcp 1mcp 11.0the mcp 1 level was determined using enzyme linked immunosorbent assays elisa .  
14597108mcp 1mcp 11.0a significant increase in cerebrospinal fluid mcp 1 level but not serum level was seen in the patients with als compared to the control subjects.  
14597108mcp 1mcp 11.0these results suggest that cerebrospinal fluid mcp 1 activity may be a sensitive marker for neuroinflammation in als useful for monitoring treatment trials in als.  
14597108mcp 1mcp 11.0especially monocyte chemoattractant protein 1 mcp 1 [ maghazachi et al. 1994 ] may be a key trigger for mediating chemotaxis of monocytes to the injured cns since it is a potent activator of macrophage function [ sozzani et al. 1995 ].  
14597108monocyte chemoattractant protein-1monocyte chemoattractant protein 11.0especially monocyte chemoattractant protein 1 mcp 1 [ maghazachi et al. 1994 ] may be a key trigger for mediating chemotaxis of monocytes to the injured cns since it is a potent activator of macrophage function [ sozzani et al. 1995 ].  
14597108mcp 1mcp 11.0mcp 1 was found immunohistochemically in mature senile plaques and reactive microglia in brain tissues of patients suffering from alzheimer's disease [ ishizuka et al. 1997 ] as well as in demyelinating pl 
14597108mcp 1mcp 11.0changes in mcp 1 in living patients with als have not been studied however its evaluation might aid in understanding the pathogenesis of the disease.  
14597108mcp 1mcp 11.0therefore the present study compares the mcp 1 level in csf and serum of patients with als with that in controls. 2.  
14597108mcp 1mcp 11.0mcp 1 levels in serum and csf samples were quantified by elisa quantikine r_amp_#x26;d systems according to the manufacturer's instructions and read at a wavelength of 450 nm reference wavelength 550 nm wi 
14597108mcp 1mcp 11.0the mann_amp_#x2013;whitney u test was used to compare mcp 1 levels in csf and serum in als patients with controls.  
14597108mcp 1mcp 11.0regression analysis was used to test for a possible relationship between age at time of lumbar puncture and intrathecal mcp 1 levels. 3.  
14597108mcp 1mcp 11.0the csf concentration of mcp 1 was significantly p _amp_#x3c;0.001 higher in als patients 570.5_amp_#xb1;199.9 pg/ml as compared to controls 285.5_amp_#xb1;81.8 pg/ml .  
14597108mcp 1mcp 11.0although an overlap of values was seen among the als group mcp 1 values of only 8 patients of 29 were lower than or equal to the highest value in the control group i.e 396.8 pg/ml .  
14597108mcp 1mcp 11.0furthermore mcp 1 levels in als patients 570.5_amp_#xb1;199.9 pg/ml were substantially higher in the csf p _amp_#x3c;0.001 than in the serum 191.6_amp_#xb1;104.9 pg/ml .  
14597108mcp 1mcp 11.0by analysis of variance there was no significant influence of age at onset of symptoms nor of duration of the disease on mcp 1 levels.  
14597108mcp 1mcp 11.0regression analysis did not reveal a strong relationship between age at time of lumbar puncture and intrathecal mcp 1 level in als patients r =0.045; fig 1a or control patients r =0 12; fig 1b . 4.  
14597108mcp 1mcp 11.0this is the first study demonstrating that mcp 1 inflammatory signalling might mediate recruitment of myelomonocytic cells to areas of neurodegeneration in als.  
14597108mcp 1mcp 11.0the present findings provide in vivo evidence for elevated cerebrospinal fluid levels of mcp 1 in als patients providing further evidence for the hypothesis that inflammatory processes contribute to neurodegeneration in als.  
14597108mcp 1mcp 11.0the higher levels of mcp 1 in the csf than in paired serum samples in patients with als provide evidence for intrathecal synthesis of this chemokine.  
14597108mcp 1mcp 11.0we hypothesize that degeneration of motor neurons in the lumbar spinal cord with subsequent activation of astrocytes and microglial cells induces a release of mcp 1 a chemokine produced by both glial cell types [ hayashi et al. 1995 ].  
14597108mcp 1mcp 11.0since mcp 1 is a potent activator of macrophage function and specifically attracts myelomonocytic cells [ calvo et al. 1996 and glabinski et al. 1997 ] it most likely triggers further immigration/activation of m 
14597108mcp 1mcp 11.0therefore one might speculate that mcp 1 might further increase during the course of als.  
14597108mcp 1mcp 11.0repetitive measurement of mcp 1 may be a useful laboratory marker to follow up patients participating in neuroprotective drug trials.  
14597108mcp 1mcp 11.0due to the lack of correlation between clinical impairment/progression of the disease and csf mcp 1 levels a larger sample size may be needed to address this specific question.  
14597108mcp 1mcp 11.0from a clinical perspective it would be interesting to explore the potential of immunotherapies specifically targeting mcp 1 dependant mechanisms in als.  
14597108monocyte chemoattractant protein-1monocyte chemoattractant protein 11.0monocyte chemoattractant protein 1 deficiency is protective in a murine stroke model [ hughes et al. 2002 ].  
14597108mcp 1mcp 11.0in experimental autoimmune encephalomyelitis absence of mcp 1 in mice leads to decreased local macrophage recruitment and antigen specific t helper cell type 1 immune response [ huang et al. 2001 ].  
14597108mcp 1mcp 11.0of note is that bindarit an indazolic derivative able to inhibit mcp 1 is able to ameliorate adjuvant arthritis in rats [ guglielmotti et al. 2002 ].  
14597108mcp 1mcp 11.0the present data suggest that mcp 1 levels in csf may be an appropriate surrogate marker in the diagnosis or in treatment of patients with als.  
14597108mcp 1mcp 11.0furthermore it would be worthwhile to examine the prognostic value of csf/plasma mcp 1 ratios in als patients who are followed longitudinally which should be done in further studies.  
14597108mcp 1mcp 11.0correlation between age at the time of lumbar puncture and intrathecal mcp 1 levels in als patients a and control patients b .  
15210305mcp 1mcp 11.0in alzheimer's disease ad for example amyloid beta a beta deposition activates astrocytes and oligodendrocytes to produce chemokines mcp 1 and rantes which act as potent in vitro microglial and macrophage chemoattractants [ 46 ].  
15962273monocyte chemoattractant protein-1monocyte chemoattractant protein 11.0production of monocyte chemoattractant protein 1 in amyotrophic lateral sclerosis.  
15962273mcp 1mcp 11.0monocyte chemoattractant protein 1 mcp 1 is critical for recruitment of inflammatory cells of monocytic lineage after inflammation or injury to the central nervous system.  
15962273monocyte chemoattractant protein-1monocyte chemoattractant protein 11.0monocyte chemoattractant protein 1 mcp 1 is critical for recruitment of inflammatory cells of monocytic lineage after inflammation or injury to the central nervous system.  
15962273mcp 1mcp 11.0mcp 1 concentrations were measured by an enzyme linked immunosorbent assay in the cerebrospinal fluid csf and the serum of 27 patients with als and 30 patients with noninflammatory neurological diseases.  
15962273mcp 1mcp 11.0in als circulating mcp 1 levels were significantly increased in the serum and particularly in the csf.  
15962273mcp 1mcp 11.0immunoreactivity for mcp 1 in als spinal cord was detected mostly in astrocytes but also in microglia neurons and within the vasculature of the cord.  
15962273mcp 1mcp 11.0our findings suggest a role for mcp 1 as an important molecular mediator of the injury response in als.  
16624536mcp 1mcp 11.0increased levels of monocyte chemoattractant protein 1 mcp 1 are seen in the cerebrospinal fluid csf from als patients [98] and [99] .  
16624536monocyte chemoattractant protein-1monocyte chemoattractant protein 11.0increased levels of monocyte chemoattractant protein 1 mcp 1 are seen in the cerebrospinal fluid csf from als patients [98] and [99] .  
16624536mcp 1mcp 11.0monocyte chemoattractant protein 1 mcp 1 is critical for migration of monoctyes to areas of injury.  
16624536monocyte chemoattractant protein-1monocyte chemoattractant protein 11.0monocyte chemoattractant protein 1 mcp 1 is critical for migration of monoctyes to areas of injury.  
16624536mcp 1mcp 11.0as discussed in relation to adaptive and acquired immunity in als mcp 1 concentrations are significantly increased in both serum and cerebrospinal fluid csf from als patients.  
16624536mcp 1mcp 11.0mcp 1 immunoreactivity is highest in astrocytes in als spinal cord suggesting that astrocytes have an important role in mediating the inflammatory response to injury in als [98] .  
16753239mcp 1mcp 11.0zolidinediones which are commonly used to treat type ii diabetes and the naturally occurring 15d pgj 2 inhibited no as well as the cytokines il 1_amp_#x3b2; il 6 and tnf _amp_#x3b1; and the chemokine mcp 1 by both primary mouse microglia and astrocytes storer et al. 2005a and storer et al. 2005b .  
16753239mcp 1mcp 11.0cently demonstrated that a variety of ppar _amp_#x3b1; agonists inhibit the production of no as well as the pro inflammatory cytokines tnf _amp_#x3b1; il 1_amp_#x3b2; il 6 il 12 p40 and the chemokine mcp 1 by primary mouse microglia.  
16753239mcp 1mcp 11.0similarly fenofibrate and 9 cis ra acted in an additive manner in inhibiting lps induction of no tnf _amp_#x3b1; il 1_amp_#x3b2; il 6 and mcp 1 expression in primary astrocytes unpublished data .  
17569578mcp 1mcp11.0ppar_amp_#x3b3; agonists have been shown to reduce the expression of the monocytic chemoattractant mcp1 [95] ip 10 cxcl3 mig and i tac [117] .  
18464925mcp 1mcp 11.0noic acids ifn= interferon il= interleukin inos= inducible nitric oxide synthase jak= janus activated kinases lbd= ligand binding domain lps= lipopolysaccharide mapk= mitogen activated protein kinase mcp 1= monocyte chemoattractrant protein 1 mhc= major histocompatibility complex ms= multiple sclerosis nf _amp_#x003ba; b= nuclear factor _amp_#x003ba; b no= nitric oxide nsaids= nonsteroidal anti inflamm 
18464925mcp 1mcp 11.0microglial activation also when elicited by gram positive bacteria staphylococcus aureus by inhibiting the expression of proinflammatory cytokines and the chemokine monocyte chemoattractant protein 1 mcp 1 [ 73 78 ].  
18464925monocyte chemoattractant protein-1monocyte chemoattractant protein 11.01; [ 63 77 ]. 15d pgj 2 attenuated microglial activation also when elicited by gram positive bacteria staphylococcus aureus by inhibiting the expression of proinflammatory cytokines and the chemokine monocyte chemoattractant protein 1 mcp 1 [ 73 78 ].